Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motesanib in recurrent ovarian, fallopian tube, or primary peritoneal cancer
NCT00574951Phase 2Terminated
- Sponsor
- GOG Foundation
- Start
- Dec 2007
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of motesanib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by GOG Foundation. Started Dec 2007; status: terminated.
02
Drugs
motesanib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00574951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00574951.